Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :901
Small font sizeDefault font sizeIncrease font size
Navigate here
  Search
 
  
Resource links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (1,648 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)  

 
  In this article
 »  Abstract
 »  References
 »  Article Figures

 Article Access Statistics
    Viewed548    
    Printed23    
    Emailed0    
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal

 

  Table of Contents  
CASE REPORT
Year : 2022  |  Volume : 59  |  Issue : 2  |  Page : 279-281
 

Expression of mismatch repair proteins in urothelial carcinoma of the urinary bladder


1 Department of Pathology and Lab Medicine, AIIMS, Bhubaneswar, Odisha, India
2 Department of Urology, AIIMS, Bhubaneswar, Odisha, India

Date of Submission24-Feb-2021
Date of Decision30-Jun-2021
Date of Acceptance11-Jul-2021
Date of Web Publication29-Jun-2022

Correspondence Address:
Suvradeep Mitra
Department of Pathology and Lab Medicine, AIIMS, Bhubaneswar, Odisha
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijc.IJC_225_21

Rights and Permissions

 » Abstract 


Background: Urothelial carcinoma of the urinary bladder (UCUB) is a frequently diagnosed malignancy. Mismatch repair (MMR), a proofreading machinery of the DNA, prevents tumorigenesis. The role of MMR deficiency in UCUB in eastern Indian population is not known.
Methods: Immunohistochemistry panel for MLH1, PMS2, MSH2, and MSH6 (MMR proteins) was performed on the biopsy specimens of UCUB (N=100).
Results: MMR deficiency by immunohistochemistry was demonstrated in two cases (2%). One case showed deficiency of MSH2 and MSH6 and the other case showed the deficiency of all four mismatch proteins. Both cases showed high-grade invasive urothelial carcinoma by histomorphology.
Conclusion: The prevalence of MMR deficiency by immunohistochemistry is 2% in eastern Indian population.


Keywords: Urothelial carcinoma; Urinary bladder; Mismatch repair; Immunohistochemistry


How to cite this article:
Mohamedali R, Adhya AK, Mandal S, Mitra S. Expression of mismatch repair proteins in urothelial carcinoma of the urinary bladder. Indian J Cancer 2022;59:279-81

How to cite this URL:
Mohamedali R, Adhya AK, Mandal S, Mitra S. Expression of mismatch repair proteins in urothelial carcinoma of the urinary bladder. Indian J Cancer [serial online] 2022 [cited 2022 Sep 28];59:279-81. Available from: https://www.indianjcancer.com/text.asp?2022/59/2/279/348457




The carcinoma of the urinary bladder is the 10th most frequently diagnosed malignancy worldwide and accounts for approximately 7% of cancer in men and 3% in women.[1] Mismatch repair (MMR) proteins aid in the proofreading of the newly replicated DNA. MMR deficiency predisposes and promotes errors in the DNA (deoxyribonucleic acid) strands denoted by microsatellite instability (MSI). The role of MMR deficiency in the tumorigenesis of lower urinary tract malignancies is only recently highlighted with a relatively high (0%–43%) prevalence in a few Western studies, although the Indian data are scarce.[2],[3],[4] We aimed at detecting the prevalence of MMR deficiency in urothelial carcinoma of the urinary bladder (UCUB) in our population by immunohistochemical analysis along with elucidation of their clinico-histomorphological features.

We employed an immunohistochemistry panel of four MMR proteins (MLH1, PMS2, MSH2, and MSH6) on 100 consecutive cases of UCUB (62% high grade; 38% low grade; pTa 43%; pT1 38%; pT2 16%; pT3 1%; pT4 2%) diagnosed in our institute (obtained by transurethral resection of bladder tumor [TURBT] 87% or cystectomy 13%). Complete absence of the nuclear expression of any MMR proteins (repeated twice) with positive internal controls (lymphocytes, endothelial cells, and stromal cells) was considered negative (absence of MMR proteins; MMR deficiency).

The mean age of the patients with urothelial carcinoma was 59.8 years (range: 20–90 years, standard deviation: 13.3). Only 17% of the subjects (n=17) were young adults (age <50 years). There was a preponderance of men (men:women = 5.7:1) (85 men and 15 women). The majority of the men were farmers (52.1%)(n=44), and the women were homemakers (20%)(n=3). More than half of the patients (52%)(n=52) were either addicted to cigarette smoking (26%)(n=26), pan chewing (22%)(n=22), or bidi smoking (14%)(n=14).

Hematuria (87%)(n=87), dysuria (20%)(n=20), abdominal pain (6%)(n=6), and palpable mass (4%)(n=4) were the common presentations. Besides, four cases (4%) were detected incidentally. About 3% of the cases (n=3) had a prior history of other malignancies, two with ureteric carcinoma, and one with renal cell carcinoma. On radiography, the most common location of these tumors was right and left lateral walls (73%)(n=73), followed by posterior walls (36%)(n=36).

MMR deficiency by immunohistochemistry was demonstrated in two cases (2%). Both these cases showed high-grade invasive urothelial carcinoma (pT1) in TURBT specimens with the limitation of detrusor muscle sampling. Both the biopsies showed the presence of necrosis (25% and 5%) and tumor-infiltrating lymphocytes (Case 1 > Case 2), respectively. The first case (a 60-year-old lady) presented with two episodes of hematuria in a month and showed a deficiency of MSH2 and MSH6 [Figure 1]. The lady remained asymptomatic after 6 months of follow-up. The second case (a 66-year-old gentleman) showed a deficiency of all four MMR proteins [Figure 2]. He presented with intermittent hematuria for the past 6 years, increased frequency and urgency for 1 year, and dysuria with suprapubic pain for the past 1 month. The patient was a chronic tobacco chewer for the previous 30 years. He had an endoluminal mass measuring 8 cm that extended till the lateral pelvic wall. He was put on neoadjuvant chemotherapy (gemcitabine). On a follow-up period of 12 months, the patient was found to be symptomatic on and off. None of these cases showed the occurrence of any synchronous or metachronous malignancy. No special or variant histological pattern was noted in either of these cases.
Figure 1: Immunohistochemistry panel of Case 1 showing deficiency of MSH2 and MSH6 proteins while MLH1 and PMS2 expressions were retained. (Note the lymphocytes, stromal, and endothelial cells as positive internal controls especially in the MMR-deficient immunostains)

Click here to view
Figure 2: Immunohistochemistry panel of Case 2 showing deficiency of all four mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6)

Click here to view


The index study showed a 2% frequency of MMR deficiency in the UCUB by immunohistochemistry. This result is in concordance with a few other previous studies.[5],[6] The variability in the results between the various studies could be attributed primarily to the difference in the selection criteria, sample size, sampling bias, and ethnicity. The application of different diagnostic modalities (immunohistochemistry or polymerase chain reaction [PCR]-based techniques) is another reason for the variability of the frequency with the PCR-based techniques estimating a higher frequency as high as 72%.[2],[4] We have not employed a parallel PCR-based technique to highlight and characterize the mutants/methylation status of the MLH1 and MSH2 genes due to the limitation of resources. This is the major limitation of the index study.

The index study estimated the prevalence of MMR deficiency in our population (2%) highlighting the role of MMR deficiency in the pathogenesis of a small subset of UCUB. Hematuria, high-grade invasive morphology, presence of necrosis, and presence of tumor-infiltrating lymphocytes are the common accompanying features.

Ethical clearance

This study has been approved by the Institutional Ethics Committee (IEC/PG Thesis/AIIMS BBSR/2018-19/11).

Acknowledgments

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Kaur S, Gupta A, Gulwani HV. A clinicopathological and immunohistochemical study of non-urothelial bladder tumours. Indian J Cancer 2019;56:254-60.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Bonnal C, Ravery V, Toublanc M, Bertrand G, Boccon-Gibod L, Hénin D, et al. Absence of microsatellite instability in transitional cell carcinoma of the bladder. Urology 2000;55:287-91.  Back to cited text no. 2
    
3.
Catto JWF, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer 2003;105:484-90.  Back to cited text no. 3
    
4.
Vaish M, Mandhani A, Mittal RD, Mittal B. Microsatellite instability as prognostic marker in bladder tumors: A clinical significance. BMC Urol 2005;5:1-7.  Back to cited text no. 4
    
5.
Kassem HS, Varley JM, Hamam SM, Margison GP. Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer. Br J Cancer 2001;84:321-8.  Back to cited text no. 5
    
6.
Fraune C, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kähler C, Kluth M, et al. MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. Urol Oncol Semin Orig Investig 2020;38:488-95.  Back to cited text no. 6
    


    Figures

  [Figure 1], [Figure 2]



 

Top
Print this article  Email this article
 

    

  Site Map | What's new | Copyright and Disclaimer | Privacy Notice
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow